Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3451838 · 1 trial · 1 indication
Migraine Headache Day is a calendar day on which a migraine or probable migraine headache occurs. Per International Headache Society \[IHS\] International Classification of Headache Disorders version 3 \[ICHD-3\], migraine is defined as a headache, with or without aura, of \>=30 minutes duration with both of the following required features (A) At least 2 of the following headache characteristics: Unilateral location; Pulsatile quality; Moderate or severe pain intensity; Aggravation by or causing avoidance of routine physical activity (B) During headache at least 1 of the following: Nausea and/or vomiting; Photophobia and phonophobia. Least square mean was assessed using Bayesian Mixed Model Analysis with baseline number of monthly migraine headache days as a covariate.
| Arm | Type | Description |
|---|---|---|
| 1500 milligrams (mg) LY3451838 | EXPERIMENTAL | Participants received a single intravenous (IV) dose of 1500 mg LY3451838. |
| Placebo | PLACEBO_COMPARATOR | Participants received a single IV dose of placebo. |
| Name | Type | Description |
|---|---|---|
| LY3451838 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Must have a diagnosis of migraine with a history of migraine headaches of at least 1 year prior, and migraine onset prior to age 50. * Have completed at least 80% of required daily diary entries during the start of the study. * Have documentation of previous failure of 2 to 4 ...
Top 5 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant, Ubrogepant, MEDI0618 |
| Pfizer Inc. | PFE | 11 | PHASE3 | Rimegepant, Zavegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
LY3451838 is an investigational small molecule being developed by Eli Lilly and Company for migraine. It has been studied in a Phase 2 clinical trial and is not yet approved. The program is in clinical development, with one completed trial of 38 participants.
LY3451838 is being studied as a treatment for migraine. It is an investigational small molecule developed by Eli Lilly and Company. The only reported trial enrolled 38 adults with migraine in the United States, and the drug has not been approved for any use.
LY3451838 is made by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the developer of the investigational small molecule for migraine.
LY3451838 is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are ongoing. The drug remains investigational and has not been approved by the FDA for migraine or any other indication.
LY3451838 has been studied in one completed Phase 2 trial, NCT04498910, titled A Study of LY3451838 in Participants With Migraine. The trial enrolled 38 adults, was randomized, double-blind, and placebo-controlled, and was conducted in the United States.